Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Ref: ADL/SE/2019-20 February 6, 2020

To, Listing/ Compliance Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 **Corporate Office :** Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel.: 022-2407 2249 / 2401 9025 (30 Lines) Fax: 022-2407 3462 / 2407 0144 Email: audit@aartidrugs.com website: www.aartidrugs.com CIN No.: L37060MH1984PLC055433

To,

Listing/ Compliance Department National Stock Exchange of India Limited, "Exchange Plaza", Bandra - Kurla Complex, Bandra (E), Mumbai – 400051

BSE CODE – 524348

Dear Sir/Madam,

Ref: Compliance of Regulation 33 of the SEBI (LODR)Regulations,2015

NSE SYMBOL: AARTIDRUGS

Sub: Audited Standalone and Consolidated Financial Results for the Quarter and nine months ended December 31, 2019

We wish to inform you that the Board of Directors at its Meeting held on **Thursday, February 6, 2020,** approved the Audited Standalone and Consolidated Financial Results for the Quarter and nine months ended December 31, 2019.

Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015 we enclose the following:-

- Audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2019.
- Auditor's Report on Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2019.

Further please make note that the Company has already made necessary arrangements to publish the same in the newspapers as required under the SEBI (LODR) Regulations, 2015.

The meeting of the Board of Directors commenced at 12:15 PM and concluded at 5:50 PM

Kindly take the same on record.

Thanking you,

Yours faithfully, FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M.No.: A54527



					AARTI DRU	IGS LIMITED)						
			STATEMENT	OF AUDITED FIN	ANCIAL RESUL	TS FOR THE QU	JARTER ENDED	31st Dec, 2019			(Rs.	in lakhs except	for share data)
-		Standalone						Consolidated					
			Quarter Ended			Ended	Year Ended		Quarter Ended			Ended	Year Ended
Sr.	Particulars	31st Dec 2019	30th Sep 2019	31st Dec 2018	31st Dec 2019	31st Dec 2018	31st Mar 2019	31st Dec 2019	30th Sep 2019	31st Dec 2018	31st Dec 2019	31st Dec 2018	31st Mar 2019
No.		(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
		14 504	44,271	35,065	122,835	102,171	145,425	47,351	47,750	38,011	135,645	110,181	156,094
1	Revenue from operations	41,561 13	44,271	35,065	122,835	102,171	628	47,351	47,750	17	50	118	618
11	Other income Total Income (1 + II)	41,575	44,292	35.086	122,879	102,296	146.053	47.376	47,769	38.027	135,694	110,299	156.712
1	Total liconie (1+ ii)	41,575	44,232	33,000	122,013	102,200	140,000	41,010	47,705	00,021	100,004	110,200	100,112
IV	Expenses :												
1V	(a) Cost of materials consumed	25,951	28,721	25.670	80,676	70,029	93,014	27,898	30,175	27,562	85,930	75,478	99,890
	(b) Purchase of stock-in-trade	1,141	879	805	2,984	2,421	3,262	2,792	1,688	1,115	6,186	3,166	4,425
1	(c) Changes in inventories of finished goods,	301	(406)	(3,579)	(2,893)	(4,706)	1,905	333	(221)	(3,399)	(2,538)	(4,796)	1,682
1	work-in-progress and stock-in-trade												
1	(d) Excise duty/taxes on goods sold					-	-	-	-	-		-	-
1	(e) Employee benefits expense	1,502	1,491	1,308	4,414	3,889	5,314	1,734	1,714	1,486	5,075	4,447	6,092
	(f) Finance costs	808	808	987	2,496	2,783	3,756	839	854	1,048	2,626	2,962	3,996
	(g) Depreciation and amortisation expense	1,185	1,155	1,024	3,468	3,011	4,039	1,236	1,209	1,072	3,626	3,175	4,256
1	(h) Other expenses	6,736	7,064	5,766	19,973	15,857	22,001	7,845	7,564	6,062	21,941	16,740	23,268
	Total expenses (IV)	37,625	39,713	31,981	111,118	93,284	133,291	42,677	42,983	34,945	122,846	101,172	143,609
1		0.050	4.500	0.405	44 704	9,011	12,762	4,699	4,787	3,083	12,848	9,127	13,102
V	Profit before exceptional items and tax (III - IV)	3,950	4,580	3,105	11,761	9,011	12,762	4,699	4,787	3,083	391	9,127	13,102
VI	Exceptional items	3,950	4.580	3,105	11,761	9.011	12,762	4,308	4,787	3,083	12,457	9,127	13,102
VII	Profit before tax (V - VI)	3,950	4,560	3,105	11,701	9,011	12,702	4,300	4,707	3,003	12,457	5,127	10,102
VIII	Tax Expenses : Provision for taxation - Current	1,150	1,300	740	3,325	2.240	3.300	1,390	1,338	742	3,636	2,272	3,372
	- MAT credit	1,150	1,000	140	0,020	2,240	5,500	1,000	1,000	142	0,000		(8)
	- Earlier year	_	-			-	(108)	-		-	-		(108)
1	Provision for deferred taxation	125	200	250	525	615	845	140	218	252	567	625	871
	Total tax expenses (VIII)	1,275	1,500	990	3,850	2,855	4,037	1,530	1,555	994	4,203	2,896	4,127
IX	Profit/(Loss) for the period from continuing operations(VII-												
		2,675	3,080	2,115	7,911	6,156	8,726	2,778	3,231	2,089	8,254	6,231	8,975
×	Profit / (Loss) form discontinuing operations	-	-	-	-	-		-	-	-	-	-	-
XI	Tax expenses of discontinuing operations	-	-	-	-	-	-	-		-	-	-	-
XII	Profit /(Loss) from discontinuing operations (X - XI)	-	-	-	-	-	-	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX - XII)	2,675	3,080	2,115	7,911	6,156	8,726	2,778	3,231	2,089	8,254	6,231	8,975
XIV	Other Comprehensive Income	4	-	-	4	-	99	4		-	4	-	99
XV	Total Comprehensive Income for the period (XIII+XIV)	2,679	3,080	2,115	7,916	6,156	8,825	2,782	3,231	2,089	8,259	6,231	9,074
XVI	Paid up equity share capital (face value of Rs.10 each)	2,330	2,330	2,358	2,330	2,358	2,358	2,330	2,330	2,358	2,330	2,358	2,358
XVII	Earning per equity share (in Rs.) (not annualised)												
	Durft study to be to a												
XVII	Profit attributable to :	2.674.71	3.079.76	2,114.60	7,911,31	6.156.50	8,725,81	2.778.29	3.231.19	2.088.61	8,254,45	6,231.00	8,975,15
	Owner of the Company	2,014.11	3,079.76	2,114.00	7,911.51	0,100.50	0,725.01	(0.20)	5,251.19	2,000.01	(0.20)	0,201.00	-
	Non- Controlling Interest	-		-		-		(0.20)			(0.20)	-	
XIX	Total Comprehensive Income attributable to :												
1	Owner of the Company	2.678.97	3.079.76	2.114.60	7,915.57	6,156,50	8.824.69	2,782.36	3,231,19	2,088.61	8,258.53	6,231.00	9,074.03
	Non- Controlling Interest	2,010.01	-	-	-	-	-		-	-	-	-	-
1	(1) Basic	11.48	13.22	8.97	33.83	26.11	37.42	11.92	13.87	8.86	35.29	26.42	38.48
	(2) Diluted	11.48	13.22	8.97	33.83	26.11	37.42	11.92	13.87	8.86	35.29	26.42	38.48

Notes

1 The above results for the quarter and period ended 31st December' 2019 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 6th February' 2020.

2 The Board of Directors have recommended Interim Dividend of Rs.2/- per Equity Share of Rs. 10/- each (20 %) amounting to Rs.4,66,00,000/- for the Financial Year 2019-20.

3 Exceptional items includes estimated loss of Rs. 391.04 Lakhs on assets held for sale.

4 The Company has only one business segment i.e. pharmaceuticals.

5 Figures for the previous Quarter have been regrouped or rearranged wherever necessary.

The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India 6 Limited www.nseindia.com for the benefit of the shareholders and investors.

Place: Mumbai Date: 6th February' 2020

For AARTI DRUGS LIMITED

HARSHIT M. SAVLA (JT. Managing Director)



2 H rugs

Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India) Tel .: 022-2407 2249 / 2401 9025 (30 Lines) Fax.: 022-2407 3462 / 2407 0144 Email: admin@aartidrugs.com website: www.aartidrugs.com CIN No.:L37060MH1984PLC055433

Manufacturers of : Bulk Drugs & Chemicals mited

KIRTANE 🌜 PANDIT

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF AARTI DRUGS LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly financial results of Aarti Drugs Limited ("the company") for the quarter ended December, 2019 and the year to date results for the period from April 01, 2019 to December 31, 2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended December 31, 2019 as well as the year to date results for the period from April 01, 2019 to December 31, 2019.

Basis for Opinion

KIA

*

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial FR results that give a true and fair view of the net profit and other comprehensive and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim

H/16, Saraswat Colony, Sitladevi Temple Road, Mahim, Mumbai - 400 016. India | T: +91 22 2444 4119, 15 / 2446 9713 | F: +91 22 2444 1147 | E: kpcamumbai@kirtanepandit.com Regd. Office : 5th Floor, Wing A, Gopal House, S. No. 127/1B/1, Plot-A1, Opp. Harshal Hall, Pune - 411 029, India | T: +91 20 6729 5100, 2543 3104, 8764 | F: +91 20 2544 7603 | www.kirtanepandit.com

Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Kirtane & Pandit LLP, Chartered Accountants FRN: 105215W/W100057

Milind Bhave Partner M No. 047973 UDIN: 20047973AAAAAO3025

Place: Mumbai. Date: February 06, 2020



KIRTANE <u> ANDIT</u>

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF AARTI DRUGS LIMITED

Report on the audit of the Consolidated Financial Results

Opinion

105210

ered Accour

We have audited the accompanying Statement of Consolidated Financial Results of Aarti Drugs Limited ("Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group") for the quarter ended December 31, 2019 and for the period from April 01, 2019 to December 31, 2019 ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Attention is drawn to the fact that the Consolidated figures for the corresponding quarter ended December 31, 2018 and the corresponding period from April 01, 2018 to December 31, 2018, as reported in these financial results have been approved by the holding company's Board of Directors.

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, the Statement:

- a. includes the results of the following entities:
 - i. Pinnacle Life Science Private Limited (Wholly-owned Subsidiary Company)
 - ii. Aarti Speciality Chemicals Limited (Wholly-owned Subsidiary Company)
 - iii. Pinnacle Chile SPA (Subsidiary Company)
- b. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- c. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of Consolidated total comprehensive income (comprising of net profit and other comprehensive income) and other financial information of the Group for the quarter ended December 31, 2019 and for the period from April 01, 2019 to 8 PANO, December 31, 2019.



Page 1 of 5

H/16, Saraswat Colony, Sitladevi Temple Road, Mahim, Mumbai - 400 016. India | T: +91 22 2444 4119, 15 / 2446 9713 | F: +91 22 2444 1147 | E: kpcamumbai@kirtanepandit.com Regd. Office : 5th Floor, Wing A, Gopal House, S. No. 127/1B/1, Plot-A1, Opp. Harshal Hall, Pune - 411 029, India | T: +91 20 6729 5100, 2543 3104, 8764 | F: +91 20 2544 7603 | www.kirtanepandit.com

Basis for Opinion

red Acco

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

These quarterly financial results as well as the year to date Consolidated financial results have been prepared on the basis of the interim financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these Consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability Anot the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated financial results or, if such disclosures are inadequate, to

W100057

ed Accour

modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Consolidated financial results, including the disclosures, and whether the Consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Consolidated financial results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, such other auditors remain responsible for the direction, supervision and performance of the audit dutors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

& PAN

ered Acco

The Consolidated Financial Results include the audited Financial Results of 2 Wholly-owned Subsidiary Companies whose interim Financial Statements / Financial Results / Financial Information reflect Group's share of total revenue of **Rs. 6,719.68 Lakhs** and **Rs. 15,804.64 Lakhs** and Group's share of total net profit after tax of **Rs. 114.31 Lakhs** and **Rs. 363.11 Lakhs** for the quarter ended December 31, 2019 and for the period from April 01, 2019 to December 31, 2019 respectively, as considered in the Consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on interim Financial Statements / Financial Results / Financial Information of these entities have been furnished to us and our opinion on the Consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

The Consolidated Financial Results include the unaudited Financial Results of a Subsidiary Company, whose interim Financial Statements / Financial Results / Financial Information reflect Group's share of total revenue of **Rs. Nil** and **Rs. Nil** and **Group's** share of total net loss of **Rs. 3.74 Lakhs** and **Rs. 3.74 Lakhs** for the quarter ended December 31, 2019 and for the period from April 01, 2019 to December 31, 2019 respectively, as considered in the Consolidated Financial Results. These unaudited interim Financial Statements / Financial Results / Financial Information have been furnished to us by the Board of Directors and our opinion on the Consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of this Subsidiary Company is based solely on such unaudited interim Financial Statements / Financial Results / Financial Information. In our opinion and according to the information and explanations given to us by the Board of Directors, these interim Financial Statements / Financial Results / Financia

Our opinion on the Consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results / Financial Information certified by the Board of Directors.

For Kirtane & Pandit LLP, Chartered Accountants FRN: 105215W/W100057

Milind Bháve Partner M No. 047973 UDIN: 20047973AAAAAP7198

Place: Mumbai Date: February 06, 2020.

